Which has better valuation and earnings, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 78.43 -$67.85M -$0.26 N/A Moderna $1.94B 29.57 -$2.82B -$7.99 N/A

Is OCGN or MRNA more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Moderna -141.43% -28.30% -19.39%

Does the media prefer OCGN or MRNA?

In the previous week, Moderna had 12 more articles in the media than Ocugen. MarketBeat recorded 26 mentions for Moderna and 14 mentions for Ocugen. Moderna's average media sentiment score of 0.56 beat Ocugen's score of -0.08 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, OCGN or PFE?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 78.43 -$67.85M -$0.26 N/A Pfizer $62.58B 2.52 $7.77B $0.76 36.43

Is OCGN or PFE more profitable?

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Pfizer 6.80% 19.63% 8.46%

Does the media prefer OCGN or PFE?

In the previous week, Pfizer had 20 more articles in the media than Ocugen. MarketBeat recorded 34 mentions for Pfizer and 14 mentions for Ocugen. Pfizer's average media sentiment score of 0.88 beat Ocugen's score of -0.08 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 22 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Is DMRA or OCGN more profitable?

Damora Therapeutics, Inc. Common Stock's return on equity of -176.39% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Ocugen N/A -127,987.80% -115.95%

Does the media favor DMRA or OCGN?

In the previous week, Ocugen had 10 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 14 mentions for Ocugen and 4 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.85 beat Ocugen's score of -0.08 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OCGN or RXRX?

In the previous week, Ocugen had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Ocugen and 3 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.42 beat Ocugen's score of -0.08 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OCGN or SNDX more profitable?

Ocugen has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Syndax Pharmaceuticals' return on equity of -372.94% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Syndax Pharmaceuticals -87.52% -372.94% -39.11%

Does the media refer more to OCGN or SNDX?

In the previous week, Ocugen had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for Ocugen and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Ocugen's score of -0.08 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ocugen (OCGN) Competitors

$1.02 -0.01 (-0.49%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.04 +0.02 (+1.96%)

As of 09/11/2026 07:59 PM Eastern

Compare

OCGN vs. MRNA, PFE, DMRA, RXRX, and SNDX

Should you buy Ocugen stock or one of its competitors? Ocugen's main competitors and comparable companies include Moderna (MRNA), Pfizer (PFE), Damora Therapeutics, Inc. Common Stock (DMRA), Recursion Pharmaceuticals (RXRX), and Syndax Pharmaceuticals (SNDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Moderna	-141.43%	-28.30%	-19.39%

Ocugen has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A
Moderna	$1.94B	29.57	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 12 more articles in the media than Ocugen. MarketBeat recorded 26 mentions for Moderna and 14 mentions for Ocugen. Moderna's average media sentiment score of 0.56 beat Ocugen's score of -0.08 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 831.37%. Moderna has a consensus target price of $76.72, indicating a potential downside of 46.71%. Given Ocugen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Ocugen and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Ocugen (NASDAQ:OCGN) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Pfizer	6.80%	19.63%	8.46%

In the previous week, Pfizer had 20 more articles in the media than Ocugen. MarketBeat recorded 34 mentions for Pfizer and 14 mentions for Ocugen. Pfizer's average media sentiment score of 0.88 beat Ocugen's score of -0.08 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	22 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 831.37%. Pfizer has a consensus price target of $28.39, indicating a potential upside of 2.52%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Ocugen has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A
Pfizer	$62.58B	2.52	$7.77B	$0.76	36.43

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pfizer beats Ocugen on 11 of the 16 factors compared between the two stocks.

How does Ocugen compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock's return on equity of -176.39% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Ocugen	N/A	-127,987.80%	-115.95%

Ocugen has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 56.58%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 831.37%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Ocugen had 10 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 14 mentions for Ocugen and 4 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.85 beat Ocugen's score of -0.08 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ocugen beats Damora Therapeutics, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Ocugen compare to Recursion Pharmaceuticals?

Ocugen (NASDAQ:OCGN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 831.37%. Recursion Pharmaceuticals has a consensus target price of $8.06, indicating a potential upside of 151.88%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Ocugen has higher earnings, but lower revenue than Recursion Pharmaceuticals. Ocugen is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A
Recursion Pharmaceuticals	$74.68M	22.94	-$644.76M	-$1.04	N/A

In the previous week, Ocugen had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Ocugen and 3 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.42 beat Ocugen's score of -0.08 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ocugen has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Summary

Ocugen beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Syndax Pharmaceuticals?

Ocugen (NASDAQ:OCGN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Ocugen has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Syndax Pharmaceuticals' return on equity of -372.94% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Ocugen has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

In the previous week, Ocugen had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for Ocugen and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Ocugen's score of -0.08 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen currently has a consensus price target of $9.50, suggesting a potential upside of 831.37%. Syndax Pharmaceuticals has a consensus price target of $42.30, suggesting a potential upside of 132.67%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Ocugen has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A

10.3% of Ocugen shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ocugen beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$345.89M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.92	14.18	274.94	25.33
Price / Sales	78.43	1,375.01	685.45	111.12
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	-25.50	15.12	10.33	6.20
Net Income	-$67.85M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-25.00%	-4.34%	-3.32%	-2.35%
1 Month Performance	-27.14%	-0.02%	-0.41%	-2.77%
1 Year Performance	-4.67%	40.64%	19.21%	7.63%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	1.7244 of 5 stars	$1.02 -0.5%	$9.50 +831.4%	-4.7%	$345.89M	$4.41M	N/A	80	Trending News Insider Trade Analyst Revision
MRNA Moderna	2.1298 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+467.0%	$55.09B	$1.94B	N/A	4,700	Trending News Analyst Forecast Gap Up
PFE Pfizer	2.911 of 5 stars	$28.51 +2.0%	$28.28 -0.8%	+11.5%	$159.36B	$62.58B	37.51	75,000	Analyst Forecast
DMRA Damora Therapeutics, Inc. Common Stock	2.9473 of 5 stars	$28.18 -2.8%	$44.00 +56.1%	+903.6%	$1.79B	N/A	N/A	40	News Coverage
RXRX Recursion Pharmaceuticals	1.4535 of 5 stars	$3.40 +1.8%	$8.06 +137.1%	-34.0%	$1.79B	$74.68M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, DMRA, RXRX, and SNDX

How does Ocugen compare to Moderna?

Summary

How does Ocugen compare to Pfizer?

Summary

How does Ocugen compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Ocugen compare to Recursion Pharmaceuticals?

Summary

How does Ocugen compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, DMRA, RXRX, and SNDX

How does Ocugen compare to Moderna?

Is OCGN or MRNA more profitable?

Which has more risk and volatility, OCGN or MRNA?

Which has better valuation and earnings, OCGN or MRNA?

Does the media prefer OCGN or MRNA?

Do institutionals and insiders have more ownership in OCGN or MRNA?

Do analysts recommend OCGN or MRNA?

Summary

How does Ocugen compare to Pfizer?

Is OCGN or PFE more profitable?

Does the media prefer OCGN or PFE?

Do analysts prefer OCGN or PFE?

Which has more risk & volatility, OCGN or PFE?

Which has preferable valuation and earnings, OCGN or PFE?

Do institutionals & insiders believe in OCGN or PFE?

Summary

How does Ocugen compare to Damora Therapeutics, Inc. Common Stock?

Do insiders and institutionals hold more shares of DMRA or OCGN?

Which has more risk & volatility, DMRA or OCGN?

Is DMRA or OCGN more profitable?

Which has higher valuation & earnings, DMRA or OCGN?

Do analysts rate DMRA or OCGN?

Does the media favor DMRA or OCGN?

Summary

How does Ocugen compare to Recursion Pharmaceuticals?

Do analysts recommend OCGN or RXRX?

Which has better valuation & earnings, OCGN or RXRX?

Does the media prefer OCGN or RXRX?

Do institutionals & insiders have more ownership in OCGN or RXRX?

Which has more volatility & risk, OCGN or RXRX?

Is OCGN or RXRX more profitable?

Summary

How does Ocugen compare to Syndax Pharmaceuticals?

Is OCGN or SNDX more profitable?

Which has more volatility & risk, OCGN or SNDX?

Does the media refer more to OCGN or SNDX?

Do analysts recommend OCGN or SNDX?

Which has higher valuation & earnings, OCGN or SNDX?

Do insiders & institutionals hold more shares of OCGN or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools